Arnold Lippa

Company: RespireRx Pharmaceuticals Inc

Job title: CEO and CSO

Seminars:

Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA) 10:00 am

Looking at Dronabinol’s potential to stabilize respiratory patterns and augment upper airway muscles Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption Enhancing Dronabinol stability and ease of manufacturing to support commercial scaleRead more

day: Conference Day 1

Re-Purposing Dronabinol Using Proprietary Formulations for New Therapeutic Indications, Specifically Obstructive Sleep Apnea (OSA) 9:30 am

Looking at Dronabinol’s potential to stabilize respiratory patterns and augment upper airway muscles Introducing drug formulation innovation in the form of proprietary lipid nanoparticle technology to enhance solubility and absorption Enhancing Dronabinol stability and ease of manufacturing to support commercial scaleRead more

day: Day One AM